Carbonic Anhydrase IX in Tumor Tissue and Plasma of Breast Cancer Patients: Reliable Biomarker of Hypoxia and Prognosis

Carbonic anhydrase IX (CA IX) is recognized as an excellent marker of hypoxia and an adverse prognostic factor in solid tumors, including breast cancer (BC). Clinical studies confirm that soluble CA IX (sCA IX), shed into body fluids, predicts the response to some therapeutics. However, CA IX is not included in clinical practice guidelines, possibly due to a lack of validated diagnostic tools. Here, we present two novel diagnostic tools-a monoclonal antibody for CA IX detection by immunohistochemistry and an ELISA kit for the detection of sCA IX in the plasma-validated on a cohort of 100 patients with early BC. We confirm that tissue CA IX positivity (24%) correlates with tumor grading, necrosis, negative hormone receptor status, and the TNBC molecular subtype. We show that antibody IV/18 can specifically detect all subcellular forms of CA IX. Our ELISA test provides 70% sensitivity and 90% specificity. Although we showed that this test could detect exosomes in addition to shed CA IX ectodomain, we could not demonstrate a clear association of sCA IX with prognosis. Our results indicate that the amount of sCA IX depends on subcellular CA IX localization, but more strictly on the molecular composition of individual molecular subtypes of BC, particularly on metalloproteinases inhibitor expression.

Automated summary

Carbonic anhydrase IX (CA IX) is a reliable marker for hypoxia and a poor prognostic factor in solid tumors, including breast cancer. This study presents two new diagnostic tools-a monoclonal antibody for CA IX detection by immunohistochemistry and an ELISA kit for sCA IX detection in plasma-validated on a cohort of 100 early breast cancer patients. Tissue CA IX positivity correlates with tumor grading, necrosis, negative hormone receptor status, and the TNBC subtype, while the ELISA test provides good sensitivity and specificity. The amount of sCA IX depends on the subcellular localization of CA IX and the molecular composition of different breast cancer subtypes.